Jeevan Scientific Technology Limitedの将来のP / EはN/Aです。
未来比率P / E (株価収益率)は、企業の株価と今後12ヶ月間の1株当たり利益見込額との比率です。
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Jeevan Scientific Technology Limited engages in the clinical research, data management, and information technology businesses in India. The company's services include BA/BE studies that comprise bioanalytical and clinical services, pharmacokinetic and bio-statistics, and glucose clamping; clinical trial services, such as medical writing, clinical trial management and monitoring, drug safety and clinical data management, biostatistics and statistical programming, and quality assurance; and pharmacovigilance services, including ICSR management, aggregate safety reports, risk management plan, signal detection, medical information call center, and other integrated services. It also provides services in the areas of test assessment, test center of excellence, process establishment, and functional and non-functional testing. The company was formerly known as Jeevan Softech Limited and changed its name to Jeevan Scientific Technology Limited in March 2011. Jeevan Scientific Technology Limited was founded in 1999 and is based in Hyderabad, India.